Can-Fite BioPharma (CANF) Total Current Liabilities (2014 - 2026)

Can-Fite BioPharma (CANF) has 13 years of Total Current Liabilities data on file, last reported at $2.2 million in Q2 2026.

• For the quarter ending Q2 2026, Total Current Liabilities rose 4.95% year-over-year to $2.2 million; the trailing twelve-month figure through Jun 2026 stood at $2.2 million (up 4.95% YoY), and the FY2025 full-year result was $2.7 million, up 33.09% from the prior year.
• Total Current Liabilities was $2.2 million for Q2 2026 at Can-Fite BioPharma, down from $2.7 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $2.9 million in Q1 2022 to a low of $2.0 million in Q2 2024.
• A 5-year average of $2.4 million and a median of $2.2 million in 2026 frame the typical range for Total Current Liabilities.
• Across the five-year window, Total Current Liabilities soared 41.04% in 2022 and decreased 20.96% in 2023, its largest moves.
• Can-Fite BioPharma's Total Current Liabilities stood at $2.5 million in 2022, then fell by 19.26% to $2.0 million in 2023, then climbed by 1.58% to $2.1 million in 2024, then soared by 33.09% to $2.7 million in 2025, then decreased by 18.53% to $2.2 million in 2026.
• Per Business Quant data, the three most recent Total Current Liabilities figures were $2.2 million in Q2 2026, $2.7 million in Q4 2025, and $2.1 million in Q2 2025.